Ebola

Global Viral Hemorrhagic Fever Treatment Market to Surpass USD 2.20 Billion By 2031| Growth Market Reports

Retrieved on: 
Monday, June 12, 2023

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics.

Key Points: 
  • The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics.
  • Moreover, it provides crucial strategies that are helping market players to expand their market share.
  • For Any Questions on This Report: https://growthmarketreports.com/enquiry-before-buying/3851
    On the basis of region, the global viral hemorrhagic fever treatment market is classified as North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
  • North America is projected to dominate the global market because it has a well-established R&D laboratory.

Global Viral Hemorrhagic Fever Treatment Market to Surpass USD 2.20 Billion By 2031| Growth Market Reports

Retrieved on: 
Monday, June 12, 2023

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics.

Key Points: 
  • The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics.
  • Moreover, it provides crucial strategies that are helping market players to expand their market share.
  • For Any Questions on This Report: https://growthmarketreports.com/enquiry-before-buying/3851
    On the basis of region, the global viral hemorrhagic fever treatment market is classified as North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
  • North America is projected to dominate the global market because it has a well-established R&D laboratory.

Kinnos Co-Founder and Chief Innovation Officer Jason Kang Named a Notable Leader in Health Care by Crain’s New York Business

Retrieved on: 
Monday, May 15, 2023

Kinnos , the maker of Highlight®, a novel technology that colorizes disinfectants, today announced that its Co-Founder and Chief Innovation Officer Jason Kang has been named a Notable Leader in Health Care by Crain’s New York Business.

Key Points: 
  • Kinnos , the maker of Highlight®, a novel technology that colorizes disinfectants, today announced that its Co-Founder and Chief Innovation Officer Jason Kang has been named a Notable Leader in Health Care by Crain’s New York Business.
  • Kang was selected for his achievements in global health, including the development of Highlight and his work with hospitals to establish new standards in infection prevention.
  • “Congratulations to Jason for this well-deserved honor,” said Kinnos CEO Steve Fanning.
  • As the Chief Innovation Officer of Kinnos, Kang continues to oversee the extension of the Highlight product line and its formulation while working closely with hospitals to improve infection prevention practices, standards and associated outcomes.

Kinnos Raises Additional $15M and Names Industry Veteran as CEO to Meet Growing Commercial Demand for Novel Color Additive to Disinfection Solutions

Retrieved on: 
Tuesday, May 2, 2023

The company also named healthcare veteran Steve Fanning as Chief Executive Officer and a member of the Board of Directors.

Key Points: 
  • The company also named healthcare veteran Steve Fanning as Chief Executive Officer and a member of the Board of Directors.
  • Founded during the Ebola outbreak in West Africa in 2015, Kinnos has steadily expanded its family of solutions at a time when disinfection and cleaning are paramount.
  • Following the COVID-19 global pandemic, Kinnos has tapped Fanning and a seasoned cadre of investors to fuel rapid growth amidst urgent demand for more effective disinfection.
  • With this latest funding, Kinnos is poised to establish a new standard of care for cleanliness in healthcare and beyond.

AIM ImmunoTech Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, April 3, 2023

OCALA, Fla., April 03, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, today reported its financial results for the fourth quarter and full year 2022 and provided a business update. As previously announced, the Company will host its inaugural conference call and audio webcast, today, Monday, April 3, 2023, at 8:30 AM ET (details below).

Key Points: 
  • Our team is committed to the development of Ampligen for unmet medical needs in cancers, immune disorders and viral diseases.
  • AIM’s goal is to generate near- and long-term value for all stockholders,” commented Thomas K. Equels, Chief Executive Officer of AIM.
  • As of December 31, 2022, AIM reported cash and cash equivalents of $34.2 million, compared to $48.3 million as of December 31, 2021.
  • Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference Call.

AstriVax, an innovative vaccine platform company, establishes scientific advisory board with world renowned leaders in vaccine development

Retrieved on: 
Friday, March 24, 2023

Leuven, Belgium, 24 March 2023 – AstriVax has announced that Dr Emmanuel Hanon will chair the company’s scientific advisory board.

Key Points: 
  • Leuven, Belgium, 24 March 2023 – AstriVax has announced that Dr Emmanuel Hanon will chair the company’s scientific advisory board.
  • Renowned infectious disease experts Dr Peter Piot and Dr Patrick Soentjens have been appointed as the first scientific advisors to the AstriVax scientific advisory board that is being composed.
  • With the support of its scientific advisory board, AstriVax will continue to build its innovative plug-and-play vaccine platform to address important unmet needs in global health.
  • Their combined experience covers the full spectrum of infectious diseases, prophylactic and therapeutic vaccine development and global health management.

Launching an Innovative Product, PlaClin-M, for Safe Environments in the Pandemic Era.

Retrieved on: 
Thursday, March 23, 2023

CodeSteri started from the Korean government project to combat new infectious diseases by the incumbent professor and MD of Hanyang University Emergency Medicine, Seoul.

Key Points: 
  • CodeSteri started from the Korean government project to combat new infectious diseases by the incumbent professor and MD of Hanyang University Emergency Medicine, Seoul.
  • PlaClin was awarded as an "Innovative Product" by the Ministry of Science and ICT and patented in USA and Korea.
  • Such airlines as Korean Airlines, Japan Airlines, and other major airlines can benefit a lot from using innovative PlaClin solutions.
  • They can offer more safe travel environments to their customers and cost saving to themselves.

Launching an Innovative Product, PlaClin-M, for Safe Environments in the Pandemic Era.

Retrieved on: 
Thursday, March 23, 2023

CodeSteri started from the Korean government project to combat new infectious diseases by the incumbent professor and MD of Hanyang University Emergency Medicine, Seoul.

Key Points: 
  • CodeSteri started from the Korean government project to combat new infectious diseases by the incumbent professor and MD of Hanyang University Emergency Medicine, Seoul.
  • PlaClin was awarded as an "Innovative Product" by the Ministry of Science and ICT and patented in USA and Korea.
  • Such airlines as Korean Airlines, Japan Airlines, and other major airlines can benefit a lot from using innovative PlaClin solutions.
  • They can offer more safe travel environments to their customers and cost saving to themselves.

AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease

Retrieved on: 
Thursday, March 16, 2023

Highlights of the recently published Ampligen data that was presented include:

Key Points: 
  • Highlights of the recently published Ampligen data that was presented include:
    As a TLR3 agonist, Ampligen induces and enhances innate immunological responses to EBOV infection.
  • AIM CEO Thomas K. Equels commented, “In vivo pre-clinical analysis shows that Ampligen has potential as both a prophylactic and an early-onset therapeutic in Ebola virus disease.
  • Animal studies with Ampligen at the United States Army Medical Research Institute of Infectious Diseases Biosafety Level 4 laboratories demonstrated 100% protective survival, as compared to 100% mortality in Ebola virus disease.
  • Ultimately, the Company's goal is to seek a Tropical Disease Priority Review Voucher for new drug applications associated with these indications.

AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease

Retrieved on: 
Wednesday, March 8, 2023

Ebola virus (EBOV) is a highly infectious and lethal pathogen responsible for sporadic, self-limiting clusters of Ebola virus disease (EVD) in Central Africa capable of reaching epidemic status.

Key Points: 
  • Ebola virus (EBOV) is a highly infectious and lethal pathogen responsible for sporadic, self-limiting clusters of Ebola virus disease (EVD) in Central Africa capable of reaching epidemic status.
  • Previously announced data found that Ampligen provided 100% protection against EVD in a mouse model.
  • The newly published analysis supports a dual mechanism of action when Ampligen is used as a prophylactic therapy against EVD.
  • Ultimately, the Company's goal is to seek a Tropical Disease Priority Review Voucher for new drug applications associated with these indications.